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Available online 6 July 2016Background: The Early Cancer Detection Consortium is developing a blood-test to screen the general population
for early identiﬁcation of cancer, and has therefore conducted a systematic mapping review to identify blood-
based biomarkers that could be used for early identiﬁcation of cancer.
Methods: A mapping review with a systematic approach was performed to identify biomarkers and establish
their state of development. Comprehensive searches of electronic databases Medline, Embase, CINAHL, the
Cochrane library and Biosiswere conducted inMay 2014 to obtain relevant literature on blood-based biomarkers
for cancer detection in humans. Screening of retrieved titles and abstracts was performed using an iterative sift-
ing process known as “data mining”. All blood based biomarkers, their relevant properties and characteristics,
and their corresponding references were entered into an inclusive database for further scrutiny by the
Consortium, and subsequent selection of biomarkers for rapid review. This systematic review is registered
with PROSPERO (no. CRD42014010827).
Findings: The searches retrieved 19,724 records after duplicate removal. The data mining approach retrieved
3990 records (i.e. 20% of the original 19,724), which were considered for inclusion. A list of 814 potential
blood-based biomarkers was generated from included studies. Clinical experts scrutinised the list to identify
miss-classiﬁed and duplicate markers, also volunteering the names of biomarkers that may have been missed:
no new markers were identiﬁed as a result. This resulted in a ﬁnal list of 788 biomarkers.
Interpretation: This study is the ﬁrst to systematically and comprehensively map blood biomarkers for early de-
tection of cancer. Use of this rapid systematic mapping approach found a broad range of relevant biomarkers
allowing an evidence-based approach to identiﬁcation of promising biomarkers for development of a blood-
based cancer screening test in the general population.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Systematic review1. Introduction
Early detection of cancer results in improved survival (Etzioni et al.,
2003; Wolf et al., 2010; McPhail et al., 2015). Cancers detected early re-
quire less extensive treatment and are less likely to have spread to other
organs. Cancer diagnosis requires histological examination of tissue ab-
normalities detected by radiological, clinical or endoscopic examination
of patients. Detection, as opposed to diagnosis, relies on screening a
largely asymptomatic population to identify people who may be at
higher risk of having cancer than others. Screening tests for cancer, oriversity Hospitals Coventry and
V2 2DX, UK.
B.V. This is an open access articleany other condition need to fulﬁl strict criteria to prevent the imple-
mentation of inappropriate screening, ensuring screening is cost effec-
tive and beneﬁts patients. The criteria applied within the UK are listed
at http://www.screening.nhs.uk/criteria, based on those developed by
Wilson and Jungner (Cochrane & Holland, 1971; Wilson & Jungner,
1968). For early cancer detection, a blood-based screening test would
have to be cost effective and demonstrate a meaningful clinical beneﬁt
which outweighs the harms associated with false positive, indetermi-
nate results and overtreatment. This is clearly a major undertaking,
and needs a multidisciplinary approach.
The Early Cancer Detection Consortium (ECDC) was established in
2012 in the United Kingdom and comprises 23 universities, their associ-
ated NHShospitals, aswell as other organisations and industry partners.
The consortium was established to investigate whether a cost-effective
screening test can be used in the general population to identify peopleunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Eligibility criteria for the systematic mapping review.
Inclusion criteria Exclusion criteria
English language studies Studies published in non-English language
Studies within the last ﬁve years
(2010–2014)
Studies from 2009 or older
Controlled studies No healthy control group
Validation studies Derivative studies from included papers
Cancer detection/diagnosis Prognosis or prediction (treatment response)
associated markers
50 or more patients Less than 50 patients
Biomarkers measured in blood Tissue or other bodily ﬂuid samples
Abstracts of panels which do not state which
biomarkers are studied
Citation titles without abstracts
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for cancer, it is logical to explore the development of such a test using
existing biomarkers that have the best evidence-base for cancer detec-
tion. A sensitive blood test for multiple tumour types could enable peo-
ple with biomarker levels which are outside the typical range to receive
further investigation and lead to earlier diagnosis of cancer at an asymp-
tomatic stage when curative treatment is feasible. The next stage of the
programme will involve analytical and clinical validation of these bio-
markers in a case control study, from which a detection algorithm will
be produced and validated for possible use as a generic cancer screen.
Finally, a randomised controlled trial will be required to determine the
clinical and cost-effectiveness of the resulting screening strategy.
Previous reviews in this area have understandably been limited in
scope, usually restricted to one biomarker or well-deﬁned group of po-
tential markers, due to the enormous number of publications in the
ﬁeld. The aim of this study was therefore to establish the full range of
candidate blood-based biomarkerswith potential for the early detection
of cancer, and map key characteristics of the tests.
2. Methods
To identify all relevant biomarkers, comprehensive searches and
innovative methods to perform the mapping review were employed
to cope with the sizeable body of relevant literature to be assessed
within a short time-frame. The mapping review comprised the follow-
ing stages: comprehensive literature searches; data mining techniques
for rapid screening of the search records and; development of a custom-
izable database of evidence to optimise the output from the mapping
review. It was not considered sufﬁcient simply to list evidence by
reference or to name the biomarker once in a spreadsheet and continue
searching until another new biomarker was found. Instead it was more
useful and time-efﬁcient to maintain the corresponding citations for
each biomarker and record the basic characteristics of the study at the
time of screening. This enabled a basic informative proﬁle to be built
for each biomarker identiﬁed in the mapping review.
This systematic review is registered with PROSPERO (no.
CRD42014010827) and the methods have been structured around the
PRISMA checklist (http://www.prisma-statement.org/).
2.1. Eligibility Criteria
Eligible studies included all English language studies from the past
ﬁve years that investigated blood based biomarkers inmore than 50 pa-
tients, see Table 1.
2.2. Search Strategy
To identify a comprehensive body of literature from which a list
of candidate biomarkers could be generated, a broad search using
keywords and subject headings was undertaken. The terms reﬂectedthe concepts of ‘diagnosis’, ‘markers’, ‘blood’ and ‘screening’ (see
supplementary material). The keywords and subject headings were
developed using a variety of collaborative methods between
Information Specialists and Systematic Reviewers at the University
of Shefﬁeld and researchers at the University of Warwick.
A scoping search was performed and assessed for appropriateness.
Additionally, key journal articles and abstracts in Medline were re-
trieved and assessed to obtain relevant subject headings and keywords.
Clinical input was sought from members of the ECDC to verify and val-
idate the chosen keywords. For the full search, relevant free-text, key-
word and thesaurus terms were combined using Boolean operators
and translated into database speciﬁc syntax. Full searches were limited
to English language, humans and publication dated from 2010 to May
2014. The databases searched were Medline and Medline in Process,
Embase, CINAHL, Cochrane Library (including Cochrane Database of
Systematic Reviews, DARE, CENTRAL, HTA, NHS EED), Science Citation
Index Expanded, Conference Proceedings Citation Index - Science,
Book Citation Index – Science, and Biosis Previews.
The initial search strategy was broad and inclusive. As a result, a
large number of relevant records were obtained. Preliminary validation
by consulting experts in the ﬁeld indicated that the searchwas sensitive
and no missing relevant literature was identiﬁed.
2.3. Sifting and Data Mining
The results of the initial searches were imported into a Reference
Manager database. To identify an exhaustive list of biomarkers, re-
trieved records were searched iterativelywithin the ReferenceManager
database, using keywords to select potentially relevant titles. Titles and
abstracts of this selection of citations were scrutinised for names and
descriptions of biomarkers that met (or potentially met) the selection
criteria (see Table 1). The citations were tagged to indicate that they
had been viewed, to enable their exclusion from further searches. Rele-
vant citations were exported to a Microsoft Access database which was
customised to allow data extraction of relevant key information for each
biomarker that was available from the corresponding study abstracts.
The data mining process within the main database included the fol-
lowing restrictions (see Box 1):
To ensure a comprehensive capture of all relevant biomarkers, a fur-
ther validation stagewas performed. Relevant reviews identiﬁed during
the search were used to check for additional biomarkers not generated
by the datamining process. ECDCmemberswere invited to recommend
papers that they believed to be relevant to the mapping review.
2.4. Data Collection
Each biomarker occupied a record with a unique identiﬁer number
in a customised Microsoft Access database which stored the number
of associated papers, the abstract and reference details; associated syn-
onyms and acronyms; types of cancers and study design; keywords
used to retrieve the abstract duringdatamining; assays used tomeasure
the biomarker, where reported; category to which the biomarker was
assigned (e.g. auto-antibodies); and the sample types used, where re-
ported (e.g. serum, plasma or whole blood).
2.5. Results
After duplicates were removed, 19,724 records were yielded from
the comprehensive searches. Using data mining, 3990 titles and ab-
stracts were retrieved from the 19,724 records for full scrutiny. Data
mining is the process of pulling a subset of records from a large, un-
wieldy dataset. The subset of 3990 abstracts was reviewed in order to
generate a list of biomarkers which are potentially relevant to early
identiﬁcation of cancer using blood. A full breakdown of the keywords
used and the number of corresponding records retrieved can be seen
in Fig. 1. During the validation process, three relevant reviews were
ox 1
ata mining process restrictions.
Restriction Justification
1. Searches limited to last five
years.
To ensure that the biomarkers
identified and their associated
evidence is current and relevant,
searches were restricted to
records published in the last five
years (from 2010 to May 2014).
2. Data mining technique
employed, as opposed to
screening all references
Data mining involved
interrogation of search results
using relevant keywords (Box 2)
to search within the database of
total records for batches of
references. Keywords were
identified through consultation
with ECDC members for known
technologies, and for other
potentially relevant terms.
Keywords for similar concepts
(e.g. synonyms for a specific
biomarker) were grouped and
searched together. Keywords
expected to retrieve citations of
high relevance were prioritised
over those with less obvious
relevance. Further keywords were
identified by the review team by
consideration of indexing
keywords and content of studies
identified as relevant.
3. One reviewer performed the
data mining.
One reviewer screened the
references to generate the list of
biomarkers using the data mining
technique. A single reviewer
screening approach was
mitigated for by the examination
review papers and consultation
with ECDC membership during a
later validation phase. An
inclusive approach to inclusion
was adopted to minimise
inappropriate exclusions.
4. Pragmatic inclusion criteria Titles without abstracts were not
included. Equally abstracts of
primary studies or reviews which
did not name a biomarker were
not included. Titles and abstracts
retrieved from each batch of
references associated with each
keyword were assessed against
the eligibility criteria in Table 1.
Box 2
Keywords used in data mining process.
Keywords used: “systematic review”; “metabolomics”; “ELISA”;
“PCR”; “volatile organic compound”; “electronic”; “immunoas-
say”; “microRNA”; “early diagnosis”; RNA”; “biomarkers”; and
“fluorescence”.
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DBox 3
Seven biomarker groupings based on technology used for detection
Seven biomarker groupings 1. Existing tumourmarker panels (cur-
rent standard for comparison); 2. Auto-antibodies. 3. Circulating
free DNA from the tumour (ctDNA); 4. Circulating MicroRNA
(miRNA); 5. Volatile Organic Compounds (VOC); 6. Mass Spec-
troscopy (MS); 7. Other biomarkers.markers. No further biomarkers were identiﬁed either from these re-
views or from the consultation of ECDC members.
A total of 814 biomarkers were identiﬁed as potentially relevant to
the review question and were subjected to further scrutiny, identifying
duplicates and miss-classiﬁed biomarkers during a process of data
cleaning and categorising the biomarkers into groups or families.
These groups are currently arranged by molecular function in order to
map the biomarkers by biological origin. Further research using this
methodology and database into the empirical application and validation
of each biomarker will allow the biomarkers to be grouped by clinicalutility such as cancer type or platform. However, we have performed
this analysis for colorectal cancer (Table 2) and lung cancer (Table 3)
to illustrate how these data could be used to deﬁne cancer-speciﬁc bio-
markers. This resulted in a ﬁnal total of 788 biomarkers, grouped into 13
initial categories (see Supplementary Tables 1–13) as follows:
1. Adhesion and matrix proteins (n = 36). The expression of mole-
cules involved in adhesion or in formation of the connective tissue
matrix around cancer cells differ from non-neoplastic cells and ap-
pear in blood. Early work included collagen breakdown products,
which are produced as a result of increased collagen turnover, but
are not speciﬁc to particular tumour types (Paterson et al., 1991;
Berruti et al., 1995). Collagens are metabolised by matrix metallo-
proteinase proteins (MMPs), these in turn are antagonised by tissue
inhibitors of matrix metalloproteinases (TIMPs) (Roy et al., 2009).
Both MMPs and TIMPs are represented in this group. Turnover of
other matrix proteins is altered in cancer: vimentin (Ludwig et al.,
2009), laminin (Schechter & Lopes, 1990) and tenascin are included
in the list. Cancer cells have increasedmotility comparedwith non-
neoplastic cells, and show altered expression of adhesion mole-
cules. EpCAM, e-cadherin, and e-selectin are represented as blood
biomarkers in the list (Beije et al., 2015; Hauselmann & Borsig,
2014; Gires & Stoecklein, 2014). Following review, a total of 18
were removed, including one duplicate entry.
2. Auto-antibodies and immunological markers (n= 59). The major-
ity of entries in this category relate to auto-antibodies. These have
been described for a wide variety of proteins within cancer, notably
nuclear proteins such as P53 and other nuclear proteins, and occur
in many cancers (Middleton et al., 2014). Immunological markers
of interest include CRP, usually regarded as a marker of
inﬂammation.
3. Classical Tumour Markers. A total of 23 markers were included in
the ‘classical’ tumourmarker group. This includes those usedwidely
in practice, including CEA, CA125, CA15-3, CA19-9, AFP, and PSA.
Markers of lesser utility, such as LDH and HE4 were also included.
It should be noted that several of these (CA15-3 and CA19-9) refer
to different epitopes of the same antigen, MUC1, which also came
up in our searches.
4. Coagulation & angiogenic proteins. Of the 29 proteins in this
category, the majority had relatively little evidence for their
utility in early cancer detection. The markers can be sub-
categorised into those connected to angiogenesis (e.g. VEGF,
PlGF, Angiopoietins) and coagulation (e.g. plasminogen acti-
vating proteins and kallikreins). Annexins were included in
this group, though they are more often thought of as apopto-
sis associated proteins.
Fig. 1.Modiﬁed PRISMA 2009 ﬂow diagram.
167L. Uttley et al. / EBioMedicine 10 (2016) 164–1735. Cytokines, chemokines and insulin-like growth factors. 52
biomarkers were included in this group. They include a
wide range of cytokines and soluble receptors. Evidence for
these is limited, but they represent an interesting group of
proteins abnormal in cancer, measurement of which is likely
to reﬂect the profound local immune suppression and sys-
temic alteration of immunity present in cancers.6. Circulating-free DNA. This is usually abbreviated as cfDNA,
though increasingly the term circulating tumour DNA
(ctDNA) is used. While DNA is clearly a single biomarker, 39 in-
dividual biomarkers representing genes or alterations of most
interest were identiﬁed in this group, though in essence any
mutation of gene methylation marker identiﬁed would be
part of this group. While the ﬁrst descriptions of cfDNA used
Table 2
Colorectal cancer speciﬁc biomarkers from all 13 categories.
Biomarker categories
ID
no Biomarker Acronym Cancer
Adhesion and matrix proteins 7 Clusterin CLI Colorectal
12 Ep cell adhesion module (GA733-2) EpCAM (GA733-2) Colorectal
22 Metallopeptidase inhibitor 1 TIMP1; TIMP-1 Colorectal
Auto-antibodies & immunological markers 2 Anti-p53 antibodies p53; serum p53 antibodies; p53-Abs; p-53-AAB;
Anti-p53Ab
Colorectal
19 Anti-heat shock protein 60 HSP60 Colorectal
40 IL2RB IL2RB Colorectal
Classical tumour markers 3 Carcinoembryonic antigen CEA Colorectal
8 Carbohydrate antigen 19-9 CA19-9; CA199 Colorectal
Coagulation and angiogenesis molecules 2 Vascular endothelial growth factor VEGF Colorectal
8 Kininogen-1 Kininogen-1 Colorectal
23 Endothelial cell-speciﬁc molecule-1 ESM-1 Colorectal
27 Thrombomodulin THBD-M Colorectal
28 Annexin A3 ANXA3 Colorectal
Cytokines, chemokines and insulin-like growth
factors
3 Interleukin 8 IL-8 Colorectal
17 Insulin-like growth factor-binding protein-2 IGFBP-2 Colorectal
26 Brain-derived neurotrophic factor BDNF Colorectal
28 Interleukin-1ra IL-1ra Colorectal
50 TNFAIP6 TNFAIP6 Colorectal
Circulating-free DNA 3 Adenomatous polyposis coli APC Colorectal
9 Septin 9 Septin 9 Colorectal
17 Methylation of CYCD2 CYCD2 Colorectal
18 Methylation of HIC1 HIC1 Colorectal
19 Methylation of PAX 1 PAX 1 Colorectal
20 Methylation of RB1 RB1 Colorectal
21 Methylation of SRBC SRBC Colorectal
34 Line1 79 bp Line1 79 bp Colorectal
35 Line1 300 bp Line1 300 bp Colorectal
36 Alu 115 bp Alu 115 bp Colorectal
37 Alu 247 bp Alu 247 bp Colorectal
Hormones Nil Nil
Metabolic markers 1 Plasma glucose levels Plasma glucose levels Colorectal
5 3-Hydroxypropionic acid and pyruvic acid 3-Hydroxypropionic acid and pyruvic acid Colorectal
6 Alanine L-Alanine, glucuronoic lactone Colorectal
7 L-Glutamine Glutamine Colorectal
8 Sarcosine Sarcosine Colorectal
11 Choline Phosphatidylcholine; (PC) (34 : 1) Colorectal
12 Phosphatidylinositol Phosphatidylinositol Colorectal
17 L-Valine Valine Colorectal
18 L-Threonine Threonine Colorectal
19 1-Deoxyglucose 1-Deoxyglucose Colorectal
20 Glycine Glycine Colorectal
21 MACF1 MACF1 Colorectal
22 Apolipoprotein H APOH; beta-2-glycoprotein Colorectal
23 Alpha-2-macroglobulin A2M Colorectal
24 Immunoglobulin lambda locus IGL@ Colorectal
25 Vitamin D-binding protein VDB Colorectal
30 2-Hydroxyglutarate 2-Hydroxyglutarate Colorectal
34 2-Hydroxybutyrate 2-Hydroxybutyrate Colorectal
35 Aspartic acid Aspartic acid Colorectal
36 Kynurenine Kynurenine Colorectal
37 Cystamine Cystamine Colorectal
50 Tricarboxylic acid TCA Colorectal
53 2-Aminoethanesulfonic acid Taurine Colorectal
54 Lactate Lactate Colorectal
55 Phosphocholine Phosphocholine Colorectal
56 Proline Proline Colorectal
57 Phenylalanine Phenylalanine Colorectal
102 Oleamide Oleamide Colorectal
111 Leukocyte methylated cytosine 5 5-mC Colorectal
116 Plasma choline-containing phospholipids Plasma phospholipids Colorectal
120 Palmitic amide Palmitic amide Colorectal
121 Hexadecanedioic acid Hexadecanedioic acid Colorectal
122 Octadecanoic acid Octadecanoic acid Colorectal
123 Eicosatrienoic acid Eicosatrienoic acid Colorectal
124 Lysophosphatidylcholine 18:2 LPC(18:2) Colorectal
125 Lysophosphatidylcholine 16:0 LPC(16:0) Colorectal
MicroRNA and other RNAs 5 let-7g Colorectal
15 miR-126 miR-126 Colorectal
32 miR-135b miR-135b Colorectal
36 miR-141 miR-141 Colorectal
38 miR-143 miR-143 Colorectal
39 miR-145 miR-145 Colorectal
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Table 2 (continued)
Biomarker categories
ID
no Biomarker Acronym Cancer
57 miR-17-3p miR-17-3p Colorectal
68 miR-18a miR-18a Colorectal
71 miR-191-5p miR-191-5p Colorectal
94 miR-20a miR-20a Colorectal
95 miR-21 miR-21 Colorectal
125 miR-29a miR-29a Colorectal
187 miR-548as-3p miR-548as-3p Colorectal
195 miR-601 miR-601 Colorectal
210 mir-760 mir-760 Colorectal
214 miR-885-5p miR-885-5p Colorectal
219 miR-92a miR-92a Colorectal
231 U6 snRNA (U6) U6 snRNA (U6) Colorectal
Novel proteins 15 Microtubule-associated protein RP/EB family
member 1
MAPRE1 Colorectal
16 Leucine-rich alpha-2-glycoprotein LRG1 Colorectal
56 Alpha-enolase Alpha-enolase Colorectal
62 Betaine Betaine Colorectal
72 CACNAG1 CACNAG1 Colorectal
82 Colon cancer speciﬁc antigen-2 CCSA-2 Colorectal
88 C9orf50-M C9orf50-M Colorectal
89 CLEC4D CLEC4D Colorectal
90 LMNB1 LMNB1 Colorectal
91 PRRG4 PRRG4 Colorectal
92 VNN1 VNN1 Colorectal
103 Dermokine-beta DK-beta Colorectal
105 Seprase Seprase Colorectal
126 Serum amyloid A SAA Colorectal
132 Lipocalin 2 Lipocalin 2 Colorectal
Nuclear proteins 2 k-ras k-ras Colorectal
Microbial proteins Nil Nil
Volatile organic compounds 1 Phenyl methylcarbamate Phenyl methylcarbamate Colorectal
2 Ethylhexanol Ethylhexanol Colorectal
3 6-t-Butyl-2,2,9,9-tetramethyl-3,5-
decadien-7-yne
6-t-Butyl-2,2,9,9-tetramethyl-3,5-decadien-7-yne Colorectal
169L. Uttley et al. / EBioMedicine 10 (2016) 164–173PCR (Lo, 2001a; Lo, 2001b), many recent papers apply multi-
analyte methods, including next generation sequencing (Coco
et al., 2015; Rothe et al., 2014; Couraud et al., 2014), to the
study of cfDNA to detect mutations of potential diagnostic sig-
niﬁcance. Though as yet few have used this for early detection.
7. Hormones. While 13 biomarkers were assigned to this category,
only Corticosteroid-binding globulin survives more stringent
searches (Wu et al., 2012). Hormone levels are not thought to be re-
liable markers of cancer.
8. Metabolomics. A large number of metabolites are known to be al-
tered in cancer, as the result of changes in energy, lipid, amino
acid, and protein metabolism. We identiﬁed 126 individual
markers, many of which were measured in concert by mass spec-
troscopy within several studies (Cross et al., 2014; Hasim et al.,
2013).
9. MicroRNA and other RNAs. There are nowover 1000 humanmiRNA
species known, a large number of these have been studied in cancer.
While the majority have been looked at in tissue, there is consider-
able interest in their possible use as a liquid biopsy, our list of 232
biomarkers in this group reﬂects this. They are rarely measured
alone: most use some form of array strategies for measurement,
most studies concentrate on single cancer types (Fortunato et al.,
2014; Clancy et al., 2014).
10. Novel Proteins. A large number of protein biomarkers, often identi-
ﬁed by mass spectroscopy or 2D gel electrophoresis, were hard to
categorise. These were grouped as novel proteins and represent a
diverse group of 148 biomarkers. Examples include alpha-2-
heremans-schmid-glycoprotein (AHSG) (Dowling et al., 2012) and
galectin (Gromov et al., 2010) in breast cancer.
11. Nuclear proteins. A group of 13 nuclear protein biomarkers were
assigned to this category, though some markers within the novel
protein group are of nuclear origin. Circulating nucleosomes areincluded in this group as they are usually detected by ELISA
(Holdenrieder et al., 2014).
12. Microbial proteins (n= 15). A small number of Epstein-Barr Virus
(EBV) and Human Papilloma Virus (HPV) proteins and their anti-
bodies have been studied as early cancer biomarkers in blood,
based on the detection of EBV DNA in cancer patients (Lo, 2001b).
Helicobacter antibodies also fall into this group.
13. Volatile Organic Compounds (VOC). Only three biomarkers, all
small metabolites, were assigned to this category, which it could
be argued forms part of the metabolite group. It is however mea-
sured differently.
3. Discussion
We systematically searched the literature from the last ﬁve years to
identify potential blood biomarkers for cancer (Hanahan & Weinberg,
2011; Cree, 2011). The data mining process retrieved 3990 citations
from the initial 19, 724 records, screening the abstracts of these citations
identiﬁed 814 biomarkers thatmay be relevant. After data-cleaning, 788
biomarkers were ﬁtted into 13 categories as described above as having
potential for use as early cancer detection biomarkers present within
blood samples. Biomarkers were grouped by molecular function. Fur-
ther analysis such as grouping by cancer type may be possible only
once the utility of each biomarker has been reviewed independently.
As this is a mapping review, it is not possible to speculate the deﬁnitive
clinical utility for each biomarker.Most studies reviewed tended to con-
centrate on single common cancers, and few papers show evidence of a
systematic approach to biomarker discovery but were limited by the
clinical samples and techniques of their laboratories.
The conduct of large systematic reviews is challenging, yet not all
biomedical questions can be reduced to the size where standard meth-
odologies for systematic review are thought reasonable. We have
Table 3
Example for lung cancer and mesothelioma speciﬁc biomarkers from all 13 categories.
Biomarker categories
ID
no Biomarker Acronym Cancer
Adhesion and matrix
proteins
2 Calreticulin CRT Lung
7 Clusterin CLI Lung
8 Cross-linked telopeptide of type I collage ICTP Lung
9 E-cadherin E-cadherin; soluble E-cadherin (sE-cad) Lung
10 E-cadherin gene CDH1 CDH1 Lung
11 E-selectin E-selectin; sE-selectin Lung
19 Matrix metalloproteinase-2 MMP2 Lung
29 Soluble L-selectin sL-selectin Lung
31 Surfactant protein-D SP-D Lung
Auto-antibodies &
immunological markers
2 Anti-p53 antibodies p53; serum p53 antibodies; p53-Abs; p-53-AAB;
Anti-p53Ab
Lung
3 Anti-survivin antibodies Survivin/anti-survivin antibodies Lung
6 Inosine monophosphate dehydrogenase IMPDH Lung
8 Immunoglobulin G IgG Lung
12 Anti-livin Livin/anti-livin antibodies Lung
22 C-reactive protein CRP Lung
28 Anti-Krebs von Lungren-6 KL-6 Lung
30 Anti-ubiquillin Ubiquillin Lung
32 Alpha-crystallin IgG antibodies Alpha-crystallin antibodies Lung
37 CD30 CD30 Lung
38 CD63 CD63 Lung
43 NY-ESO-1 NY-ESO-1 Lung
44 CAGE CAGE Lung
45 GBU4-5 GBU4-5 Lung
46 SOX2 SOX2 Lung
47 HuD HuD Lung
48 IgM autoantibodies IgM autoantibodies Lung
55 Anti-hydroxysteroid-(17-alpha)-dehydrogenase Lung
56 Anti-triosephosphate isomerase Lung
Classical tumour markers 2 Cancer antigen 15-3 CA15-3; CA 15-3 Lung
3 Carcinoembryonic antigen CEA Lung
6 Human epididymis protein 4 HE4 Lung
9 Squamous cell carcinoma antigen SCCA; SCC-ag Lung
11 Cytokeratin fragment 19 CYFRA 21-1 Lung
12 Neuron Speciﬁc Enolase NSE Lung
14 Progastrin-releasing peptide proGRP Lung
22 HER2 HER2; AB_HER2; 36 HER2 negative; erbb-2;
soluble human epidermal growth factor receptor 2
(sHER2)
Lung
Coagulation and
angiogenesis molecules
1 Urokinase plasminogen activator uPA/uPAR/suPAR Lung
2 Vascular endothelial growth factor VEGF Lung
10 Endothelin-1 ET-1 Lung
13 Angiopoietin-2 Angiopoietin-2; Apo-2 Lung
14 Thrombospondin-1 THBS1 Lung
15 Plasminogen activator inhibitor Plasminogen activator inhibitor Lung
19 Endostatin Endostatin Lung
21 Annexin A1 ANXA1 mNRA Lung
24 C4d C4d Lung
25 Annexin A2 ANXA2 Lung
Cytokines, chemokines
and insulin-like growth
factors
7 Tumour necrosis factor [alpha] TNF[alpha]; DcR3 Lung
10 Macrophage migration inhibitory factor MIF Lung
18 Hepatocyte growth factor HGF Lung
19 Insulin-like growth factor binding protein IGFBP-3 Lung
20 Granulocyte-colony stimulating factor G-CSF Lung
21 Interleukin 3 IL-3 Lung
22 Stem cell factor SCF Lung
25 C-C motif chemokine 5 C-C motif chemokine 5 Lung
28 Interleukin-1ra IL-1ra Lung
29 Monocyte chemotactic protein-1 MCP-1 Lung
31 Midkine MK; MDK Lung
38 IRF1 IRF1 Lung
51 Macrophage inﬂammatory protein 4 MIP-4 Lung
52 Megakaryocyte potentiating factor MPF Mesothelioma
Circulating-free DNA 1 Microsatellite alterations at FHIT FHIT Lung
2 Microsatellite alterations at loci on chromosome 3 3p loci Lung
3 Adenomatous polyposis coli APC Lung
4 CHD1 CHD1 Lung
5 O(6)-Methyl-guanine-DNA methyltransferase MGMT Lung
6 DCC DCC Lung
7 RASSF1A RASSF1A Lung
8 absent in melanoma 1 AIM1; beta/gamma crystallin domain-containing
protein 1
Lung
Hormones 9 Progesterone receptor B PRB Lung
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Table 3 (continued)
Biomarker categories
ID
no Biomarker Acronym Cancer
13 Prolactin Prolactin Lung
Metabolic markers 6 Alanine L-Alanine, glucuronoic lactone Lung
26 Leucine Leucine; isoleucine Lung
27 Histidine Histidine Lung
28 Tryptophan Tryptophan Lung
29 Ornithine Ornithine Lung
38 Lactic acid Lactic acid Lung
39 Glycelic acid Glycelic acid Lung
40 Glycolic acid Glycolic acid Lung
87 NG1A2F NG1A2F Lung
89 N-glycopeptides Glycopeptides Mesothelioma
102 Oleamide Oleamide Lung
103 Long chain acyl carnitines Long chain acyl carnitines Lung
104 Lysophosphatidylcholine 18:1 LPC(18:1) Lung
105 Lysophosphatidylcholine 20:4 LPC(20:4) Lung
106 Lysophosphatidylcholine 20:3 LPC(20:3) Lung
107 Lysophosphatidylcholine 22:6 LPC(22:6) Lung
108 Serum metabolite 16:0/1 SM(16:0/1) Lung
115 Ferritin FTL Lung
MicroRNA and other RNAs 7 miR-103 miR-103 Mesothelioma
14 miR-1254 miR-1254 Lung
15 miR-126 miR-126 Mesothelioma
20 miR-128b miR-128b Lung
29 miR-133a miR-133a Lung
35 miR-140 miR-140 Lung
38 miR-143 miR-143 Lung
41 miR-1468 miR-1468 Lung
43 miR-146b-3p miR-146b-3p Lung
50 miR-155 miR-155 Lung
53 miR-15b miR-15b Lung
60 miR-181c miR-181c Lung
61 miR-182 miR-182 Lung
68 miR-18a miR-18a Lung
80 miR-197 miR-197 Lung
95 miR-21 miR-21 Lung
98 miR-212 miR212 Lung
106 miR-220 miR-220 Lung
108 miR-221 miR-221 Lung
111 miR-23a miR-23a Lung
122 miR-27b miR-27b Lung
135 miR-30c-1* miR-30c-1* Lung
145 miR-330 miR-330 Lung
147 miR-331 miR-331 Lung
152 miR-339-5p miR-339-5p Lung
157 miR-345 miR-345 Lung
158 miR-346 miR-346 Lung
172 miR-377 miR-377 Lung
180 miR-484 miR-484 Lung
188 miR-548b miR-548b Lung
189 miR-550 miR-550 Lung
190 miR-566 miR-566 Lung
192 miR-574–5p miR-574–5p Lung
197 miR-616* miR-616* Lung
198 miR-625* miR-625* Mesothelioma
203 miR-656 miR-656 Lung
204 miR-660 miR-660 Lung
213 miR-876-3p miR-876-3p Lung
218 miR-92 miR-92 Lung
221 miR-939 miR-939 Lung
224 miR-let-7 let-7 Lung
Novel proteins 3 Haptoglobin HP Lung
21 CD9 CD9 Lung
22 CD81 CD81 Lung
39 HMGA1 HMGA1 Lung
40 TFDP1 TFDP1 Lung
41 SUV39H1 SUV39H1 Lung
42 RBL1 RBL1 Lung
43 HNRPD HNRPD Lung
58 Anterior gradient 2 AGR2 Lung
63 Pentraxin-3 PTX3 Lung
67 Lysyl oxidase LOX Lung
75 Death receptor 3 DR3 Lung
76 Membrane-spanning 4 domain subfamily A from the multigene family MS4A Lung
(continued on next page)
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Table 3 (continued)
Biomarker categories
ID
no Biomarker Acronym Cancer
of proteins involved in signal transduction of which CD20 is one
member
93 Heat shock protein 90 alpha HSP90alpha Lung
94 Leucine-rich repeats and immunoglobulin-like domains 3 LRIG3 Lung
95 Pleiotrophin Pleiotrophin Lung
96 Protein kinase C iota type PRKCI Lung
97 Repulsive Guidance Molecule C RGM-C Lung
98 Stem Cell Factor soluble Receptor SCF-sR Lung
99 YES YES Lung
116 HMGB1 HMGB1 Mesothelioma
119 Carbohydrate antigen 50 CA50 Lung
125 Cytokeratin fragment 21.1 Cytokeratin fragment 21.1 Lung
126 Serum amyloid A SAA Lung
128 Carbohydrate antigen 211 CA211 Lung
146 Endoplasmic reticulum protein-29 ERP29 Lung
Nuclear proteins 3 Isocitrate dehydrogenase 1 IDH1 Lung
4 p53 messenger RNA p53 mRNA Lung
10 E2F6 E2F6 Lung
13 Variant Ciz1 Ciz1 Lung
Microbial proteins 6 Epstein-Barr virus-induced gene 3 EBI3 Lung
Volatile organic
compounds
Nil Nil
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may be suitable for the early detection of cancer using the search tools
available within the reference management software. As with any ap-
proach to reviewing literature that falls short of a full systematic review,
there is a balance between rigour and expenditure of time and re-
sources. In this case, the aim was not to identify all relevant literature
(as would be the case in a systematic review of efﬁcacy), but rather all
relevant biomarkers. It should be noted that the database does not
hold the full text of the articles referenced and is restricted to titles, ab-
stracts and keywords. Full text searching using machine learning algo-
rithms could eventually provide a better solution.
In this instance, to allow a thorough search of the large dataset of
biomarker literature and ensure an efﬁcient approach to managing the
data, we used data mining tools available within the referencemanage-
ment software. This allowed us to retrieve potentially relevant records,
extract data relating to relevant biomarkers, and validate the process
through adjunctive searches of reviews and through contactwith an ex-
tensive network of experts.While the use of experts to validate the data
may be regarded as subjective, it was a necessary step in validation of
the searches and the multidisciplinary consortium involved in this
work covers a large range of expertise. The limitation to studies pub-
lished after 2009 could have skewed the data towards new technolo-
gies, and therefore reviews were included to mitigate the risk of
ignoring older methodologies. Despite this limitation, it is notable that
proteomic biomarkers, a more mature technology, formed a large pro-
portion of the biomarkers found. Furthermore, it is possible that many
of those biomarkers that have received less attention more recently
did so because they were found to have limited utility in subsequent
studies. We used conservative selection criteria that may have resulted
in the inclusion of irrelevant biomarkers, but will have minimised the
chance of relevant biomarkers being excluded. As such, we are conﬁ-
dent that ourmethodology is ﬁt for purpose andwill have had high sen-
sitivity for the identiﬁcation of relevant biomarkers.
Limiting themapping review to abstractsmay have excluded studies
identifying multiple potential biomarkers if such biomarkers were only
mentioned in the main text. This is unlikely to occur in the ﬁeld of
emerging and promising biomarkers where the aim is to highlight the
biomarker and technology to the audience. However, the vagueness of
the abstracts ofmanypapers is a challenge, as is the generally poor qual-
ity of study design. Even some larger scale studies frommajor groups do
not include controls and few studieswere powered to examinemultiple
biomarkers in comparison with existing tumour markers. The majority
of cases (when described) are from patients with advanced disease,and this is a major concern for those interested in early detection:
there is no guarantee that biomarkers identiﬁed in patients with ad-
vanced disease are relevant to thosewith early disease. There is certain-
ly a need to improve the quality of papers on early detection using tools
such as those available from the EQUATOR network (http://
www.equator-network.org).
Our intention is to use the list of biomarkers identiﬁed by this re-
view to generate a set of biomarkers that can be subjected to analyt-
ical validation within pathology blood science laboratories, then
clinically validated within a large, prospective, multicentre clinical
study to develop a generic cancer testing strategy for subsequent
clinical trial. The primary aim is to produce a screening test strategy
for cancer that does more good than harm at reasonable cost. Good
includes decreased morbidity and mortality from early detection, di-
agnosis and treatment of cancers, while harm is usually regarded as
signiﬁcant risk of overdiagnosis, and consequent overtreatment.
The entire strategy needs to be cost effective to achieve eventual ap-
proval from the UK National Screening Committee (NSC), which de-
ﬁnes 22 criteria according to the condition, the test, the treatment
and the screening programme (http://www.screening.nhs.uk/
criteria) based on those developed by Wilson & Jungner (1968).
Within the list, there are some interesting results. Firstly, it is clear
that current tumour markers, which considered in isolation, few
would regard as sensible diagnostic tests in patients with a possible di-
agnosis of cancer, are collectively quite good at detection if used concur-
rently. The bulk of the work on this comes from one group in Barcelona
(Molina et al., 2012), with other important contributions from others
(Barak et al., 2010). The validation of biomarkers needs a point of refer-
ence, for direct comparison and it is clear that tumourmarker lists used
byMolina et al. (2012) represent such a standard.Wewould encourage
those active in the ﬁeld to use this list as their comparator for future
work to allow comparison between studies.
The biomarkers can be grouped by the technology used for their de-
tection. Taken to its logical conclusion, this results in a reduction of the
thirteen groups above to seven groups as outlined in Box 3.
The ability of proteinmeasurement to bemultiplexed by immunoas-
say arrays ormass spectroscopymeans that all proteins, including auto-
antibodies, can be measured simultaneously. Simple panels with few
analyses tend to be less expensive and have greater potential for high
throughput. DNA and RNA can be detected rapidly and inexpensively
by polymerase chain reaction (PCR) technologies, and there is evidence
from multiple studies that the level of cfDNA has potential as a generic
cancer marker. However, PCR is limited in the number of targets that
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present in patients with small tumours, which does not permit large
numbers of tests to be performed without recourse to sequencing or
large panels. Sequencing has the potential to detect large numbers of
mutations, adding speciﬁcity, and could have utility in reﬂex testing. It
is currently an expensive option, but costs of sequencing are decreasing
rapidly, while technologies available are improving their capability at
almost the same pace.
Metabolomics is of considerable interest, with a large literature to
support it. While larger molecules require mass spectroscopy to mea-
sure their presence, smaller molecules can be detected in gas phase in
the head space of blood samples using inexpensive sensor technologies.
We believe that this relatively new option may have considerable po-
tential to act as a generic test. There are a number of other tests that
do not ﬁt immediately into one of these seven categories: nucleosome
assays are one such example, and are being used as potential screening
tests.
The concept of combining high sensitivity/low speciﬁcity tests with
reﬂex low sensitivity/high speciﬁcity tests to detect cancers early
(Cree, 2011), seems feasible from the results we have obtained. We
need to combine biomarkerswith high sensitivity for screening the gen-
eral populationwith biomarkers of high speciﬁcity to determine the rel-
evance of the screening results. The next task is clearly to try this in
practice to determine its real potential for early cancer detection, and
to determine the best analyticalmethods to process the data for individ-
ual patients. Our preferred strategy is to examine thebiomarkers in each
category in greater detail, and undertakedirect comparison of these bio-
markers in a large cohort of samples following independent analytical
validation. In our view, the same caveats around retrospective studies
apply to biomarker validation as they do to drug trials: the potential
for bias from sample collections is high and large prospective studies
are necessary. This review is therefore the ﬁrst step in an ambitious
programme of work which will inevitably require careful evaluation of
clinical, cost and ethical implications at each stage. However, there is
no doubt that if such an approach to early cancer detection proved suc-
cessful, it could be invaluable.
4. Conclusion
This ground-breaking study is the ﬁrst to systematically and com-
prehensively map blood biomarkers for early detection of cancer and
will inform an innovative research project to identify, validate and im-
plement new generic blood screening tests for early cancer detection
in the general population.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.004.
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